Metformin and Statin’s Effect on Prostate Cancer Risk in Diabetics with Benign Prostatic Hyperplasia
Date of Award
4-1-2021
Document Type
Open Access Thesis
Degree Name
Master of Medical Science (MMSc)
First Advisor
Harris E. Foster Jr., MD
Abstract
Prostate cancer, a leading cause of cancer mortality, is associated with benign prostatic hyperplasia. Additionally, individuals with type 2 diabetes have a diminished prostate cancer risk. Metformin and statins are routinely used in the management of diabetes; however, it is unclear whether the combination of metformin and statins can reduce the incidence of prostate cancer in men with a concurrent diagnosis of type 2 diabetes and benign prostatic hyperplasia. This study will determine whether combination treatment of metformin and statins lowers the incidence of prostate cancer in patients with benign prostatic hyperplasia and type 2 diabetes. Using a retrospective cohort study, we will compare the incidence of prostate cancer among type 2 diabetics with benign prostatic hyperplasia using both metformin and statins against cohorts using metformin only, statin only, and neither metformin nor statin. These results will elucidate metformin and statin’s role as preventative cancer modalities.
Recommended Citation
Mugno, Kevin, "Metformin and Statin’s Effect on Prostate Cancer Risk in Diabetics with Benign Prostatic Hyperplasia" (2021). Yale School of Medicine Physician Associate Program Theses. 99.
https://elischolar.library.yale.edu/ysmpa_theses/99
